Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Esteve

Showing results (271-280 of 285) with videos related to

Pageof 29
Sort By:
Leukemia|September 30, 2005
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)M Aoudjhane, M Labopin, N C Gorin, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 12, 2019
Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infectionD Viasus, P Puerta-Alcalde, C Cardozo, et al.
Leukemia|April 16, 2013
Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AMLJ F Nomdedéu, M Hoyos, M Carricondo, et al.
Blood|August 15, 2000
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groupsM A Sanz, F Lo Coco, G Martín, et al.
Bone Marrow Transplantation|December 1, 2015
Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMTX Cahu, M Labopin, S Giebel, et al.
Blood|November 11, 1999
A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA groupM A Sanz, G Martín, C Rayón, et al.
Leukemia Research|June 15, 2010
Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment sizeJ Nomdedeu, E Bussaglia, N Villamor, et al.
Leukemia Research|August 13, 2005
Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patientsG Perea, A Domingo, N Villamor, et al.
Leukemia|June 7, 2017
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapyD Martínez-Cuadrón, P Montesinos, E Vellenga, et al.
Haematologica|August 28, 2001
Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMAJ M Hernández, G Martín, N C Gutiérrez, et al.
Pageof 29

Showing results (271-280 of 285) with videos related to

Sort By:
Pageof 29
Leukemia|September 30, 2005
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)M Aoudjhane, M Labopin, N C Gorin, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 12, 2019
Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infectionD Viasus, P Puerta-Alcalde, C Cardozo, et al.
Leukemia|April 16, 2013
Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AMLJ F Nomdedéu, M Hoyos, M Carricondo, et al.
Blood|August 15, 2000
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groupsM A Sanz, F Lo Coco, G Martín, et al.
Bone Marrow Transplantation|December 1, 2015
Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMTX Cahu, M Labopin, S Giebel, et al.
Blood|November 11, 1999
A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA groupM A Sanz, G Martín, C Rayón, et al.
Leukemia Research|June 15, 2010
Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment sizeJ Nomdedeu, E Bussaglia, N Villamor, et al.
Leukemia Research|August 13, 2005
Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patientsG Perea, A Domingo, N Villamor, et al.
Leukemia|June 7, 2017
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapyD Martínez-Cuadrón, P Montesinos, E Vellenga, et al.
Haematologica|August 28, 2001
Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMAJ M Hernández, G Martín, N C Gutiérrez, et al.
Pageof 29